<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383237</url>
  </required_header>
  <id_info>
    <org_study_id>AHEAD-HNP051</org_study_id>
    <nct_id>NCT03383237</nct_id>
  </id_info>
  <brief_title>Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma</brief_title>
  <official_title>Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma：An Open-Label, Single-center, Single-arm Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm the safety and efficacy of Apatinib as the&#xD;
      Second-line Therapy in Malignant Melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma is a malignant tumor caused by hyperplasia of abnormal melanoma cells.Most of the&#xD;
      adults above 30 years of age occur in the skin, mucosa and internal organs. The investigators&#xD;
      designed the study to explore the possibility of apatinib as the Second-line Therapy in&#xD;
      Malignant Melanoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of first documented progression or date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Defined as the proportion of patients with a documented complete response, partial response, and stable disease (CR + PR + SD) based on RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 2 year</time_frame>
    <description>From date of randomization until the date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malignant Melanoma</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 500mg/d,q.d.,p.o.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>500mg/d,q.d.,p.o.</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed the informed consent form prior to patient entry.&#xD;
&#xD;
          2. Pathologically confirmed first-line treatment of advanced malignant melanoma patients&#xD;
             with at least one measurable lesion.&#xD;
&#xD;
          3. ≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group(ECOG) performance status 0 or 1.&#xD;
&#xD;
          5. Life expectancy of more than 3 months.&#xD;
&#xD;
          6. Adequate hepatic, renal, heart, and hematologic functions: ANC ≥ 1.5×109/L, PLT ≥&#xD;
             100×109/L, HB ≥ 90 g/L, TBIL ≤ 1.5×ULN, ALT or AST ≤ 2.5×ULN (or ≤ 5×ULN in patients&#xD;
             with liver metastases), Serum Cr ≤ 1.5×ULN, Cr clearance ≥ 60 mL/min;Left ventricular&#xD;
             ejection fraction (LVEF) ≥ lower limit of normal (50%).&#xD;
&#xD;
          7. Female subjects of child-bearing potential must agree to use contraceptive measures&#xD;
             starting 1 week before the administration of the first dose of apatinib until 6 months&#xD;
             after discontinuing study drug. Male subjects must agree to use contraceptive measures&#xD;
             during the study and 6 months after last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. uncontrollable hypertension (systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, despite&#xD;
             optimal medical therapy), grade II The above myocardial ischemia or myocardial&#xD;
             infarction, poor control of arrhythmia (including QTc interval male ≥ 450 ms, female ≥&#xD;
             470 ms).&#xD;
&#xD;
          2. Patients previously treated with anticancer therapies also have a Toxicity Level&gt; 1 in&#xD;
             NCI CTCAE.&#xD;
&#xD;
          3. A variety of factors that affect oral absorption (such as inability to swallow,&#xD;
             nausea, vomiting, chronic diarrhea, intestinal obstruction, etc.).&#xD;
&#xD;
          4. Patients with gastrointestinal bleeding risk may not be included, including the&#xD;
             following: (1) active peptic ulcer lesions and fecal occult blood (++); (2) history of&#xD;
             melena and vomiting within 3 months; (3) ) For fecal occult blood (+) must be&#xD;
             gastroscopy, clear whether the existence of gastrointestinal organic diseases.&#xD;
&#xD;
          5. Coagulation dysfunction (INR&gt; 1.5, PT&gt; ULN + 4s or APTT&gt; 1.5 ULN), with bleeding&#xD;
             tendency or ongoing thrombolysis or anti-blood coagulation treatment.&#xD;
&#xD;
          6. Long-term, unhealed wounds or fractures.&#xD;
&#xD;
          7. Active bleeding, within 30 days after major surgery.&#xD;
&#xD;
          8. Intracranial metastasis.&#xD;
&#xD;
          9. Pregnant or lactating women.&#xD;
&#xD;
         10. Cytotoxic drug treatment, radiotherapy within 3 weeks after treatment; had taken two&#xD;
             or more targeted drugs, or into the group before the other three months have been&#xD;
             taking other targeted drugs.&#xD;
&#xD;
         11. Other malignant tumors in the past 3 years.&#xD;
&#xD;
         12. The investigators believe there is any condition that may harm the subject or result&#xD;
             in the subject's inability to meet or perform the research requirements.&#xD;
&#xD;
         13. Huge metastasis / recurrence (tumor diameter&gt; 5 cm)。&#xD;
&#xD;
         14. Malignant pleural effusion or ascites, causing NCI CTCAE grading 2 or more people with&#xD;
             dyspnea.&#xD;
&#xD;
         15. Any allergy to apatinib should be excluded.&#xD;
&#xD;
         16. Severe liver and kidney dysfunction (grade 4) patients should be excluded.&#xD;
&#xD;
         17. Persons with a history of substance abuse who can not be abdicated or have mental&#xD;
             disorders.&#xD;
&#xD;
         18. According to the judgment of the researcher, there is a concomitant disease that&#xD;
             seriously endangers the patient's safety or affects the patient in completing the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zibing Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zibing Wang</last_name>
    <phone>18937621301</phone>
    <email>bingziwang@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zibing Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>December 18, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 24, 2017</last_update_submitted>
  <last_update_submitted_qc>December 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

